Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159143 · ClinicalTrials.gov registry record · Phase 2
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
A Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract, sponsored by Leonard Appleman.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03159143: Completed Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract, sponsored by Leonard Appleman.
NCT03159143 is a Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract that has completed, run by Leonard Appleman. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03159143, a Phase 2 study of Metastatic Transitional Cell Cancer of the Urothelial Tract, has completed, sponsored by Leonard Appleman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract. The primary endpoint was to assess response, as defined as a 25% reduction in measurable disease per the RECIST criteria. Measurable or evaluable objective response rate, time to disease progression and survival were also assessed.
Primary Outcome
Percentage of patients who experienced a greater than or equal to a 30% reduction in measurable disease, as per the RECIST criteria.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Oxaliplatin
Study Locations (1)
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-12-17 |
| Est. Completion | 2009-12-02 |
| Phase | Phase 2 |
What the finished NCT03159143 record still lists
NCT03159143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Metastatic Transitional Cell Cancer of the Urothelial Tract appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT03159143 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03159143 about?
NCT03159143 is a clinical study titled "Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract". The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract. The primary endpoint was to assess response, as defined as a 25% reduction in measurable di...
What is the current status of trial NCT03159143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2004-12-17. Estimated completion is 2009-12-02.
What conditions does trial NCT03159143 study?
This clinical trial studies the following conditions: Metastatic Transitional Cell Cancer of the Urothelial Tract.
What interventions are being tested in trial NCT03159143?
The interventions under investigation include: Docetaxel (DRUG), Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT03159143?
This trial is sponsored by Leonard Appleman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03159143 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03159143's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI